Bacteriocins are microbially produced, ribosomally synthesized peptides that have a bactericidal or bacteriostatic effect on other species. One of the two major classes of bacteriocins are lantibiotics (lanthionine-containing antibiotics) and are distinguished by the cross-linking of cysteine to either dehydroalanine or dehydrobutyrine (resulting from the dehydration of hydroxyl amino acids) to form lanthionine and/or methyllanthionine residues. Other unusual posttranslationally modified amino acids including unlinked dehydroalanines and dehydrobutyrines can also be present (reviewed in references 7, 11, 15, and 19) . The lantibiotics can themselves be subdivided on the basis of the nature of the enzymes responsible for these characteristic modifications. Type 1 lantibiotics (such as nisin, subtilin, and epidermin) are modified by a dual-enzyme system generically referred to as LanBC, while type 2 lantibiotics (such as lacticin 481, mersacidin, lacticin 3147, and cinnamycin) are modified by LanM proteins (33, 50) . Lantibiotics have been the focus of extensive research in recent years, since it was established that many of them exhibit broad-range activity against a number of clinically relevant pathogens (6, 18, 24, 31, 41) . At least some lantibiotics are active at single-nanomolar concentrations through a dual mechanism of action, which is facilitated by binding to lipid II, the "Achilles heel" of the gram-positive cell wall and a target of a number of clinically relevant antibiotics (4, 5, 48, 49) . It is unsurprising that numerous screening strategies have taken place with a view to identifying novel lantibiotics with desirable properties such as enhanced potency, target specificity, or physicochemical properties. As with producers of antimicrobials in general, lantibiotic-producing strains have traditionally been screened by functional assays based on the inhibition of specific target spoilage or pathogenic microbes. In addition to being timeconsuming, a lack of precise knowledge with respect to optimal lantibiotic-producing conditions (e.g., pH, incubation temperature, time of incubation, carbohydrate source, and temporal expression, etc.) and the use of a limited number of indicator strains can result in producing strains being overlooked. As the number of bacterial genome sequences available in public databases is increasing rapidly, it is likely that a postgenomic approach to identify novel bacteriocins may prove to be an attractive alternative.
In the current communication, we describe computational analyses employed to search sequenced bacterial genomes for novel type 2 lantibiotics. Of the putative LanM-encoding genes identified, 61 are in strains not previously reported to be producers of lantibiotics. Five strains that were subjected to closer in silico analysis revealed further evidence of the potential for the production of lantibiotic-like peptides, and one, Bacillus licheniformis ATCC 14580, through a combination of bioinformatic analyses, antimicrobial assays, mass spectrometry, and high-performance liquid chromatography (HPLC) analyses, was confirmed to be the producer of a broad-spectrum twopeptide lantibiotic, lichenicidin.
MATERIALS AND METHODS
Media, chemicals, and growth conditions. B. licheniformis ATCC 14580 (isogenic to DSM13) was obtained from the American Type Culture Collection (ATCC) and was routinely grown in either brain heart infusion broth or LuriaBertani (LB) broth at 37°C. Listeria monocytogenes (EGDe, LO28, 10403s,  CD147, CD1032, CD1028, CD1066, CD243, CD98, DPC4606, CD749, CD238,  CD878, DPC4609, CD1059 , and CD246), Listeria innocua, Bacillus cereus, Bacillus halodurans C-125, Bacillus subtilis, Streptococcus mutans 257, Streptococcus pneumoniae TIGR4, Staphylococcus aureus (ST285, ST525, ST523, ST533,  ST355, ST530, ST535, ST544, ST522 , and ST353), Enterococcus faecium (EC533, EC667, EC548, EC538, EC587, EC676, EC300, and EC89), and Enterococcus faecalis (EC618 and EC655) strains were grown in brain heart infusion broth at 37°C. Lactococcus lactis (HP, DPC3147, 104, 497, AM2, and MG1363) strains were grown in GM17 at 30°C. All media were purchased from Oxoid.
Sequence analyses. Bioinformatic analyses to identify novel lantibiotics were performed using the National Center for Biotechnology Information (NCBI) database (http://www.ncbi.nlm.nih.gov). PSI-BLAST searches (3) were performed with the lacticin 3147 modification enzyme LtnM1 (GenBank accession number NP_047321) as a driver sequence. All significant hits were examined. In selected cases, the corresponding bacterial genomes were accessed through the genome database, and the regions containing the genes of interest were located. These genomes were also analyzed by BAGEL, a Web-based bacteriocin genome-mining tool (14) . Where necessary, protein sequences were further analyzed using various Web-based programs including those located at http://psort .nibb.ac.jp/, http://www.sbc.su.se/ϳmiklos/DAS/maindas.html, http://.cbs.dtu.dk /services/TMHMM/, and http://www.ncbi.nlm.nih.gov/Structure/cdd/cdd.shtml. Protein alignments were carried out using CLUSTAL W (http://www.ebi.ac.uk /clustalw/).
Inhibition spectrum. For well diffusion assays, 20 ml of agar was seeded with 50 l of a culture of the test strain (approximately 1 ϫ 10 6 CFU/ml) grown overnight, and when set, 8-mm holes were bored with the end of a sterile glass pipette. Cell-free supernatant or crude bacteriocin preparation was diluted in Ringer's solution, and 50 l of each dilution was added to separate wells. Plates were incubated overnight at a temperature suitable for the growth of the test strain. For deferred antagonism assays, 10 l of a B. licheniformis ATCC 14580 culture grown overnight was spotted onto 20 ml of LB agar and allowed to grow at 37°C overnight. Cells were killed by a 20-min exposure to UV light, and plates were then overlaid with soft agar (0.75% agar) containing 50 l (1 ϫ 10 6 cells) of a culture of the test strain grown overnight. Plates were incubated overnight at a temperature suitable for the growth of the test strain.
Generation of a crude lantibiotic preparation. A method similar to that used previously for the purification of lacticin 3147 (9) was used to obtain a preparation of lantibiotic from whole B. licheniformis ATCC 14580 cells. A culture of B. licheniformis ATCC 14580 grown overnight was inoculated (1%) into 1 liter of LB broth and incubated at 37°C overnight (approximately 16 to 18 h) with shaking. Cells were harvested by centrifugation at ϳ7,500 ϫ g for 20 min and resuspended in 250 ml of 70% propan-2-ol (adjusted to pH 2 through the addition of concentrated HCl). After 5 h of stirring at 4°C, cell debris was removed by centrifugation, and the supernatant was reduced to approximately 60 ml by rotary evaporation, freeze-dried, and resuspended in 3 ml of 2.5 mM sodium phosphate buffer. Activity was examined by well diffusion assays using L. lactis HP as the indicator strain.
Purification of lichenicidin. B. licheniformis ATCC 14580 was grown overnight at 37°C with shaking in LB broth, after which it was inoculated (1%) into tryptone-yeast extract-glucose in conical flasks and reincubated for a further 18 h at 37°C with shaking. The culture was centrifuged at ϳ7,500 ϫ g for 20 min, and the supernatant was removed and discarded. Cell pellets were resuspended in 300 ml of 70% isopropanol-0.1% trifluoroacetic acid and stirred at room temperature for approximately 3 h. Samples were centrifuged (ϳ7,500 ϫ g for 20 min), and supernatants were retained. The isopropanol was evaporated using a rotary evaporator (Buchi) before application onto a Phenomenex SPE C 18 column preequilibrated with methanol and water. The column was washed with 120 ml of 30% ethanol, and bacteriocin was eluted in 100 ml 70% propan-2-ol (pH 2). Ten milliliters was concentrated to 1 ml by rotary evaporation and applied onto a Phenomenex C 12 reverse-phase HPLC column previously equilibrated with 25% propan-2-ol-0.1% trifluoroacetic acid. The column was developed in a gradient of 35% to 65% propan-2-ol at a flow rate of 1.2 ml/min.
Mass spectrometric analysis. For colony mass spectrometry (CMS), colonies were mixed with 50 l of 70% isopropanol (pH 2), vortexed, and centrifuged at 14,000 ϫ g for 2 min. The supernatant was removed for analysis. The mass of peptides present in this supernatant or in HPLC fractions was determined with an Axima CFR Plus matrix-assisted laser desorption ionization-time of flight mass spectrometer (Shimadzu Biotech, Manchester, United Kingdom) as previously described (25, 29) .
RESULTS

Identification of LanM homologs in sequenced genomes.
A strategy was employed to identify novel type 2 lantibiotics using an in silico approach that takes advantage of the highly conserved nature of the associated lanthionine synthetase, generically termed LanM. A representative protein, LtnM1, one of two such enzymes responsible for the modification of the two-peptide lantibiotic lacticin 3147, was selected as the driver for this screen, which involved a PSI-BLAST (3) search of the NCBI database (http://www.ncbi.nlm.nih.gov). All results with significant E values were examined. It was noted that hits below the cutoff point included known non-LanM proteins, such as type 1-associated LanC homologs, which are known to exhibit low-level sequence identity to LanM proteins (43) . In total, 89 proteins with homology to LtnM1 were apparent (Table 1 ). These included proteins previously associated with the production of the lantibiotics lacticin 3147; staphylococcin C55; mersacidin; michigainin; haloduracin; nukacin ISK-1; cytolysin; streptococcin A-FF22; mutacins II and K8; Smb; BHT-A; salivaricins A, A1, A2, 9, and B; macedocin; butyrivibriocin OR79A; ruminococcin A; lactocin S; and cinnamycin as well as 61 proteins predicted to be produced by strains not previously identified as being lantibiotic producers (Table 1). While a number of the strains are representatives of species previously associated with lantibiotic production, many are from species, genera, and even phyla for which the biosynthesis of these antimicrobials has never been reported or screened for.
Specific examination of five potential lantibiotic gene clusters. Of the potential producers, five were selected for a more detailed bioinformatics analysis, including Streptococcus pneumoniae SP23-BS72 (CGSSp23BS72_03618), Bacillus licheniformis ATCC 14580 (Bli04128), Anabaena variabilis NCPPB (Ava_ B0238), Geobacillus thermodenitrificans NG80-2 (GTNG_2062), and Herpetosiphon aurantiacus ATCC 23779 (Haur_1868). This involved an analysis of regions flanking LanM determinants for other open reading frames (ORFs) potentially involved in the biosynthesis of, or immunity to, lantibiotics (taking advantage of the fact that lantibiotic genes are often organized into one or more adjacent operons). More specifically, a screen for genes potentially encoding structural peptides (designated LanA) was undertaken. These peptides consist of a cysteineless leader region that terminates with a "GG" leader cleavage site (GG, GA, or AG) and a structural propeptide containing a number of cysteine, threonine, and serine residues that can be subsequently modified by LanM. While homology can exist between individual unmodified LanA peptides and is the basis of one approach to the classification of lantibiotics (10), LanA peptides that are completely unlike any other known peptide have been, and continue to be, identified. We also screened for other relevant genes encoding proteins involved in modification (lanB, lanC, lanM, lanD, and lanJ), processing (lanP and lanT), transport (lanT and lanH), immunity (lanI and lanFEG), and regulation (lanR, lanK, lanQ, and lanX).
Streptococcus pneumoniae SP23-BS72, a clinical pneumoniaassociated isolate (42), possesses a number of additional po- (Fig. 1) . Significantly, two neighboring small ORFs (CGSSp23BS72_03598623 and CGSSp23BS72_03598628), which we designate PnmA1 and PnmA2, respectively, potentially encode the individual prepeptides of a two-peptide lantibiotic ( Fig. 1 and 2) . Two-peptide lantibiotics are active via the synergistic activity of two lanthionine-containing peptides and include lacticin 3147, produced by Lactococcus lactis DPC3147 (38); staphylococcin C55, produced by Staphylococcus aureus C55 (32); plantaricin W, produced by Lactobacillus plantarum (20) ; Smb, produced by Streptococcus mutans GS5 (51); BHTA, produced by Streptococcus rattus BHT (21); and haloduracin, produced by Bacillus halodurans C-125 (25, 29; for a review, see reference 26). As with other such peptides, PnmA1 and PnmA2 both contain possible leader regions, which end with GG or GA leader cleavage sites ( Fig. 2A and B) . The second gene cluster studied is located on one of three plasmids found in A. variabilis ATCC 29413, a filamentous heterocyst-forming cyanobacterium. It is notable that although cyanobacteria are not known as lantibiotic producers, a number of lanM homologs listed in Table 1 (Fig. 1 ), Ava_B0235 and Ava_B0238 are predicted to be a secretion protein and the membrane domain of an ABC transporter, respectively, while the product of Ava_ b0236 is predicted to possess a number of lantibiotic propeptide-like features including a leader region devoid of cysteine residues with a GG leader cleavage motif (Fig. 2C ) and a structural portion that contains seven potentially modified serine, threonine, or cysteine residues (not shown). However, possibly the most significant feature of this peptide is the fact that related peptides are encoded by ORFs located adjacent to the lanM homologs in Myxococcus xanthus DK1622 (MXAN_ 2855, MXAN_2856, and MXAN_6389 for lanA and MXAN_ 2857 and MXAN_6388 for lanM), Stigmatella aurantiaca DW4/ 3-1 (STIAU_2782 for lanA and STIAU_2781 for lanM), and Herpetosiphon aurantiacus ATCC 23779 (Haur_3740 for lanA and Haur_3738 for lanM). This resemblance is specifically within the proposed leader regions (Fig. 2C) , which, in addition to facilitating export, possibly play a role in the recognition of the peptides by modification enzymes such as LanM enzymes during biosynthesis. G. thermodenitrificans is a thermophilic bacillus isolated from a deep oil reservoir in Northern China (17) . With respect to its putative lantibiotic-encoding gene cluster, a putative LanT determinant (GNTG_2061) as well as an unannotated possible structural peptide determinant (located between GNTG_2062 and GNTG_2063) are located in close proximity to the putative LanM-encoding gene (GNTG_2062) (Fig. 1) . The putative structural peptide again contains a leader region, which lacks cysteine residues and ends with a GG motif preceding a peptide potentially containing as many as 11 modified residues (Fig. 2D) . Response regulator, histidine kinase, and regulator determinants are also located in this region, but it is unclear if they contribute to lantibiotic production (Fig. 1) .
The fourth cluster is located in H. aurantiacus. H. aurantia- cus is a filamentous bacterium found most frequently in soil, freshwater, and sewage treatment plants. The strain with its genome sequenced, ATCC 23779, possesses two putative lantibiotic-encoding gene clusters, one of which, as noted above, contains a structural gene resembling that associated with A. variabilis ATCC 29413. The second such cluster encodes a putative LanM protein, which even more closely resembles LtnM1. Upon first examination, the corresponding genomic region lacks any other lantibiotic-associated features except for the presence of an ABC transporter determinant (Haur_1869) (Fig. 1) . However, closer inspection reveals that between Haur_1868 and Haur_1869, one finds six previously unannotated and almost identical ORFs, all of which are predicted to code for peptides with a cysteine-free, AG-ending leader as well as a structural peptide with 12 to 14 potentially modified residues (Fig. 2E) , which are the most likely target of LanMcatalyzed modification. While the presence of multiple structural peptide determinants was previously noted (e.g., macedocin has three such genes [34] ), the existence of six such copies has not previously been reported. Identification and sequence analysis of a bacteriocin-related cluster in B. licheniformis ATCC 14580. Of the five strains selected for closer inspection, B. licheniformis ATCC 14580 was the focus of particular attention due to the presence of two, nonframeshifted, LanM determinants and because the bacilli were noted to be producers of a number of potent lantibiotics. The fact that this strain is nonpathogenic and has already been the subject of research with a view to industrial applications (36) also suggested that a lantibiotic produced by this strain could potentially be clinically useful. The genetic organization of the lantibiotic-related cluster is shown in Fig. 1 . ORFs BLi04116 to BLi04128, inclusive, are predicted to encode a two-peptide lantibiotic and associated proteins involved in modification, processing, transport, immunity, and regulation. The predicted products of flanking ORFs do not seem to be bacteriocin related (BLi04115 and BLi04129 are predicted to encode a ferrochetalase and a pectate lyase, respectively). The 14-gene cluster (an additional unannotated ORF was identified between BLi04126 and BLi04127 and was designated BLi04126b) was analyzed using various Web-based programs (listed in Materials and Methods), the results of which are summarized in Table 2 . BLi04116 to BLi04118 encode the putative self-protection immunity genes lanEFG. BLi04122 encodes a putative regulator that shows significant homology (38% identity) to LtnR (GenBank accession number NP_ 047318), a transcriptional repressor of the immunity genes of the two-peptide lantibiotic lacticin 3147. BLi04124 encodes a putative serine protease that shows significant homology to CylA (37% identity) of Enterococcus faecalis (accession number AAK67268) and EpiP of S. aureus (accession number YP_ 186702) (29% identity), involved in production of the lantibiotics cytolysin and epidermin, respectively (39, 40) . BLi04125 encodes a potential transporter that is homologous to LtnT of L. lactis pMRCO1 (32% identity) (accession number CAB60262) (16) and MrsT (34% identity) (accession number NP_047322) (2) of Bacillus sp. strain HIL-Y85/54728, both of which contribute to the export and leader cleavage of lantibiotics (lacticin 3147 and mersacidin, respectively). The two LanM proteins BLi04126 and BLi04128 are 30% identical to each other but are more homologous to BH0452 and BH0453, respectively. BH0452 and BH0453 are the two modification enzymes associated with the biosynthesis of the lantibiotic haloduracin by B. halodurans (34% identity in both cases) (25, 29) . The putative BLi04119 and BLi04123 proteins do not show homology to any proteins in the public databases, so computational analyses could not predict a function. BLi04127 and BLi04126b encode the predicted lantibiotic structural peptides, designated BliA1 and BliA2 (in unmodified form) or Bli␣ and Bli␤ (modified), respectively. The presence of two structural peptide determinants, combined with the presence of two LanM determinants, suggests that, if expressed, this cluster of genes is responsible for the production of a twopeptide lantibiotic (26, 29) . With respect to both BliA1 and BliA2, putative leader peptides with a double-glycine motif were identified, indicating the presence of leader peptides of 42 and 34 amino acids, respectively. With respect to the leaderless propeptides, BliA1 and BliA2 are most homologous to HalA1 and HalA2, the corresponding leaderless propeptides of haloduracin (40% and 54% identity, respectively). BliA1 and BliA2 were aligned with the structural peptides of the six related two-peptide lantibiotics and PnmA1 and PnmA2 for comparative purposes ( Fig. 2A and B) . As a result, it was apparent that a number of residues are conserved across all peptides. These residues include a number of Cys, Ser, and Thr residues that are known to be involved in bridge formation in the corresponding lacticin 3147 and plantaricin W (20, 27, 29) as well as a Glu in the A1/␣ peptides that is involved in lipid II binding. Other than these, there are conserved Gly/Asn residues in the A1/␣ peptides and a Thr (known to be unmodified in LtnA2) in the A2/␤ equivalents that may be involved in the other conserved function of all of these peptides, namely, the ability to interact with the corresponding "sister" peptide. Viewed in combination, it is apparent that BliA1/PnmA1 and BliA2/PnmA2 contain motifs that closely resemble those previously noted as being common to all related A1 (SxxxGNxG xxCTxTxECmxxC) and A2 (s/txxxxcps/tTxCs/txxC) peptides, respectively (9, 26) (Fig. 2) . Production of an antimicrobial substance by B. licheniformis ATCC 14580 and partial purification of lichenicidin. Deferred antagonism assays confirmed that B. licheniformis ATCC 14580 produces an antimicrobial compound (Fig. 3A) . Additional assays established that all gram-positive strains tested were sensitive, including 10 L. monocytogenes strains; 10 methicillinresistant Staphylococcus aureus strains; 10 vancomycin-resistant enterococci; selected B. cereus, Streptococcus pneumoniae, and Streptococcus mutans strains; and nonpathogenic species, including L. innocua and L. lactis (data not shown). Two producers of two-peptide lantibiotics (L. lactis DPC3147, producing lacticin 3147, and B. halodurans C-125, producing haloduracin) were also inhibited, establishing that the natural immunity mechanisms in these strains do not provide protection against lichenicidin. The antimicrobial appears to be cell associated, as cell-free supernatant from B. licheniformis ATCC 14580 cultures lacked antimicrobial activity when assessed by agar well diffusion assays. CMS analysis revealed the presence of two peaks with masses of 3,020.4 and 3,251.5 Da (corresponding to the M ϩ H forms of the peptides) on the cell surface (Fig. 3B) . These masses, combined with using the structure of lacticin 3147 peptides Ltn␣ and Ltn␤ as templates (27) , allowed us to predict the structure of the Bli peptides (Fig. 3C ). In the case of Bli␣, a mass of 3,250 Da is consistent with seven dehydration reactions (i.e., a reduction in the mass of the unmodified peptide, 3,376 Da, by 126 Da). This suggests that only one hydroxy residue remains unmodified. This unmodified residue is most likely to be Ser30, as a corresponding Ser is also unmodified in Bha␣ (29) . Using the Ltn␣ structure as a template, it is likely that bridges form between residues 11 and 21, 22 and 27, and 24 and 31. Although a residue corresponding to the remaining cysteine, Cys7, is not present in Ltn␣, we predict that this forms a bridge stabilizing the N terminus of the peptide. Bridges involving the most N-terminally located residue are also a feature of Ltn␣ and Bha␣ (29) . The mass of Bli␤ (3,020 Da) is consistent with the loss of the six most N-terminally located residues, a phenomenon previously associated with Plw␣ and Bha␣ (20, 29) , and 12 dehydrations. It is highly likely that bridge formation similar to that observed for Ltn␤ (27) is occurring between residues 19 and 23, 25 and 28, and 29 and 32. An additional cysteine, Cys11, which is absent from Ltn␤, also most likely interacts with the N-terminally located residue in a manner analogous to that observed for Bha␣ (29) .
To confirm that the antimicrobial activity observed was attributable to lichenicidin, we employed a purification method first developed to purify lacticin 3147 from the surface of producing cells. The resulting extract was found to possess antimicrobial activity against indicator strains in well diffusion assays (Fig. 3A for L. lactis HP) and was also shown to retain activity when exposed to a variety of different temperatures (42°C to 100°C for 30 min, autoclaving at 121°C for 15 min, and 4°C for 7 days) and to be active over a broad range of pH values (pH 1 to 10) (data not shown). Reverse-phase HPLC analyses of this extract yielded two distinct peaks of mass corresponding to those resulting from CMS (Fig. 3D) . Well diffusion assays with HPLC fractions revealed that while each of these possessed antimicrobial activity, as with other twopeptide lantibiotics, synergism was apparent when the individual fractions were combined (Fig. 3D) .
DISCUSSION
It has been established that many lantibiotics inhibit clinically relevant pathogens, including multidrug-resistant strains (6, 18, 24, 31, 41) . Unsurprisingly, as the potential of these peptides has become more apparent, there have been renewed efforts to identify novel forms with desirable traits. Laboratorybased screening strategies continue to be successful, and re- cently, the lantibiotic planosporicin was identified as part of a strategy whereby 120,000 microbial extracts from 40,000 actinomycetes were screened for antimicrobial activity against a staphylococcal indicator strain (6) . However, with the wealth of bioinformatic data available in publicly available databases, it is now possible to identify potential lantibiotic producers by using an in silico approach. Another feature of the bioinformatic screen is the number of pathogenic bacteria previously not known to be lantibiotic producers that possess putative LanM determinants, including Streptococcus pneumoniae, Corynebacterium diphtheriae, Coxiella burnetii, and Clostridium perfringens. Thus far, cytolysin, produced by enterococci, is the only lantibiotic known to contribute to pathogenicity (8, 12) , although lantibiotic production is also a characteristic of selected strains of Staphylococcus aureus (32) , Staphylococcus epidermidis (1, 23) , Streptococcus mutans (21, 30, 35, 37, 45) , and Streptococcus pyogenes (22, 44, 47) . The addition of the agents capable of causing pneumonia, diphtheria, Q fever, and gastroenteritis to this list provides further evidence that, in addition to researching lantibiotics with a view to targeting these pathogens, there are apparent merits in assessing the contribution of lantibiotic production to the competitiveness, and therefore pathogenicity, of these organisms. One such pathogen, Streptococcus pneumoniae SP23-BS72, is potentially the producer of a two-peptide lantibiotic possessing, in addition to the two structural genes, a number of additional genes that are likely to be involved in lantibiotic production. Notably, however, the apparently frameshifted nature of the second LanM determinant may, if genuine, result in one of the two peptides not being modified, which, as a consequence of the synergistic nature of the two peptide lantibiotics, would be predicted to result in the absence of antimicrobial activity (28) .
The remaining potentially novel lantibiotic producers were both members of the Bacillaceae: G. thermodenitrificans NG80-2 and B. licheniformis ATCC 14580. Bacilli are the producers of many lantibiotics including subtilin, ericin A, ericin S, mersacidin, sublancin (reviewed in references 46), and haloduracin (25, 29) . Both NG80-2 and ATCC 14580 (17, 36) produce a number of enzymes that could have industrial applications. In both cases, a previously unannotated potential structural peptide-encoding gene was identified. While the putative NG80-2 structural peptide shares no sequence similarity with known peptides, bioinformatics revealed that ATCC 14580 was likely to be the producer of a two-peptide lantibiotic. Notably, a detailed bioinformatic analysis was required to identify a second structural peptide-encoding gene in this instance. Similarly, other putative structural peptide determinants, not annotated in the genomes of G. thermodenitrificans and H. aurantiacus, were revealed. These investigations highlight the merits of performing detailed examinations when what at first appear to be "orphan" LanM determinants, i.e., those apparently unassociated with a corresponding structural determinant, are identified.
As a consequence of the frequent association of bacilli with the production of potent antimicrobials, its nonpathogenic nature, and the likely production of a two-peptide lantibiotic (many of which possess broad-spectrum antimicrobial activity), B. licheniformis ATCC 14580 was selected for proof-of-concept studies. HPLC analysis combined with reverse-phase HPLC established that a two-peptide lantibiotic, lichenicidin, is indeed produced. Its activity against L. monocytogenes, methicillin-resistant Staphylococcus aureus, and vancomycin-resistant enterococci suggests that lichenicidin may potentially be used as a clinical therapeutic agent, but further investigations will be required to confirm this.
Although computational analyses described herein and elsewhere cannot be expected to provide a definitive list of all lantibiotic producers, they can identify excellent candidate strains for detailed "wet-lab" experiments. In silico analyses should therefore be considered an attractive alternative to traditional functional assays for the identification of novel lantibiotics.
